Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $8.25 and last traded at $8.64, with a volume of 418 shares. The stock had previously closed at $8.97.
Analyst Upgrades and Downgrades
BCYC has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Stephens reissued an "equal weight" rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. JMP Securities cut their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. Finally, B. Riley decreased their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.14.
Read Our Latest Stock Analysis on BCYC
Bicycle Therapeutics Stock Down 5.7 %
The stock has a market cap of $484.76 million, a PE ratio of -2.13 and a beta of 1.40. The business has a 50 day moving average price of $10.89 and a 200 day moving average price of $17.05.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. During the same period in the previous year, the firm earned ($1.16) EPS. The business's quarterly revenue was down 30.2% on a year-over-year basis. On average, research analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.
Insider Activity
In related news, CAO Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the transaction, the chief accounting officer now owns 32,146 shares in the company, valued at approximately $482,190. This trade represents a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 8.50% of the company's stock.
Hedge Funds Weigh In On Bicycle Therapeutics
Hedge funds have recently modified their holdings of the business. Barclays PLC lifted its position in Bicycle Therapeutics by 878.3% in the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC acquired a new position in Bicycle Therapeutics during the 4th quarter worth about $57,000. China Universal Asset Management Co. Ltd. boosted its holdings in Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after acquiring an additional 2,191 shares during the period. JPMorgan Chase & Co. grew its position in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after acquiring an additional 1,782 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Bicycle Therapeutics during the third quarter worth about $325,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
